PRELUDE THERAPEUTICS INC Earnings Per Share, Basic and Diluted
PRELUDE THERAPEUTICS INC (PRLD) reported Earnings Per Share, Basic and Diluted of -$0.63 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- PRELUDE THERAPEUTICS INC earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.63.
- PRELUDE THERAPEUTICS INC earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.70.
- PRELUDE THERAPEUTICS INC earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.66.
- PRELUDE THERAPEUTICS INC earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.58.
- PRELUDE THERAPEUTICS INC earnings per share, basic and diluted for fiscal 2021 was -$2.43.
- PRELUDE THERAPEUTICS INC earnings per share, basic and diluted for fiscal 2020 was -$4.56.
- PRELUDE THERAPEUTICS INC earnings per share, basic and diluted for fiscal 2019 was -$16.52.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.63 10-Q · filed 2022-05-10 | -$1.33 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$1.99 derived: net income ÷ weighted average shares · filed 2023-11-01 | -$2.58 derived: net income ÷ weighted average shares · filed 2023-11-01 |
| 2021-12-31 | -$0.70 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.37 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.95 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$2.43 10-K · filed 2022-03-17 |
| 2021-09-30 | -$0.66 10-Q · filed 2021-11-12 | -$1.25 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.72 10-Q · filed 2021-11-12 | -$2.18 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$0.58 10-Q · filed 2021-08-12 | -$1.06 10-Q · filed 2021-08-12 | -$1.51 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.46 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-03-31 | -$0.47 10-Q · filed 2022-05-10 | -$0.92 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.89 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.95 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2020-12-31 | -$0.45 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$1.57 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$2.96 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$4.56 10-K · filed 2022-03-17 |
| 2020-09-30 | -$5.25 10-Q · filed 2021-11-12 | -$10.69 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$15.83 10-Q · filed 2021-11-12 | -$21.37 derived: net income ÷ weighted average shares · filed 2021-11-12 |
| 2020-06-30 | -$5.50 10-Q · filed 2021-08-12 | -$10.65 10-Q · filed 2021-08-12 | -$16.19 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$20.23 derived: net income ÷ weighted average shares · filed 2021-11-12 |
| 2020-03-31 | -$5.12 10-Q · filed 2021-05-11 | -$10.67 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$14.66 derived: net income ÷ weighted average shares · filed 2021-11-12 | |
| 2019-12-31 | -$5.56 derived: net income ÷ weighted average shares · filed 2021-03-16 | -$9.53 derived: net income ÷ weighted average shares · filed 2021-03-16 | -$16.52 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$3.93 10-Q · filed 2020-11-10 | -$10.80 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |